Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation

Blood

Volumn 119, Issue 5, 2012, Pages 1130-1138

  Chen, Yun ^a,c   Kornblit, Brian ^a,d   Hamlin, Donald K ^b   Sale, George E ^a,b   Santos, Erlinda B ^a   Wilbur, D Scott ^b   Storer, Barry E ^a,b   Storb, Rainer ^a,b   Sandmaier, Brenda M ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SHANDONG UNIVERSITY   (China)

^d University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; MONOCLONAL ANTIBODY CD45 ASTATINE 211; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CHIMERA; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG DOSE ESCALATION; FOLLOW UP; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTOPENIA; MONONUCLEAR CELL; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

EID: 84863012882     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380436     Document Type: Article

References (49)

1. Appelbaum FR, Matthews DC, Eary JF, et al. Use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54(5):829-833.
2. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98(3):565-572.
3. Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009;114(27):5444-5453.
4. Schulz AS, Glatting G, Hönig M, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood. 2011;117(17):4642-4650.
5. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconjugates Radiopharmaceuticals. 1991;4(1):85-97.
6. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36(10):1902-1909.
7. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles: III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res. 1991;128(2):204-209.
8. Dadachova E. Cancer therapy with alpha-emitters labeled peptides [review]. [Erratum appears in Semin Nucl Med. 2010;40(4):219.] Semin Nucl Med. 2010;40(3):204-208.
9. Kennel SJ, Stabin M, Roeske JC, et al. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res. 1999;151(3):244-256. (Pubitemid 29109134)
10. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood. 2002;100(1):318-326. (Pubitemid 35177463)
11. Bethge WA, Wilbur DS, Storb R, et al. Radioimmunotherapy with Bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation. 2004;78(3):352-359. (Pubitemid 39095400)
12. Nakamae H, Kerbauy FR, Wilbur DS, et al. Pilot study of a 213bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation. 2010;89(11):1336-1340.
13. Bethge WA, Wilbur DS, Storb R, et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRab as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood. 2003;101(12):5068-5075. (Pubitemid 36857775)
14. Nakamae H, Wilbur DS, Hamlin DK, et al. Biodistribution, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 2009;69(6):2408-2415.
15. Caniatti M, Roccabianca P, Scanziani E, Paltrinieri S, Moore PF. Canine lymphoma: immunocytochemical analysis of fine-needle aspiration biopsy. Vet Pathol. 1996;33(2):204-212. (Pubitemid 126484262)
16. Moore PF, Rossitto PV, Danilenko DM, Wielenga JJ, Raff RF, Severns E. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high density expression of CD4 by canine neutrophils. Tissue Antigens. 1992;40(2):75-85.
17. Barsoukov AA, Moore PF, Storb R, Santos EB, Sandmaier BM. The use of an anti-TCRab monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation. 1999;67(10):1329-1335. (Pubitemid 29252408)
18. Sandmaier BM, Storb R, Appelbaum FR, Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood. 1990;76(3):630-635. (Pubitemid 20251835)
19. Sandmaier BM, Schuening FG, Bianco JA, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5(2):125-130.
20. Denkers E, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 1985;135(3):2183-2186. (Pubitemid 16240056)
21. Jacobsen CN, Aasted B, Broe MK, Petersen JL. Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopathol. 1993;39(4):461-466. (Pubitemid 24023355)
22. Wilbur DS, Hamlin DK, Vessella RL, et al. Antibody fragments in tumor pretargeting: evaluation of biotinylated Fab′ colocalization with recombinant streptavidin and avidin. Bioconjug Chem. 1996;7(6):689-702. (Pubitemid 27012711)
23. Wilbur DS, Vessella RL, Stray JE, Goffe DK, Blouke KA, Atcher RW. Preparation and evaluation of para-[211At]astatobenzoyl labeled antirenal cell carcinoma antibody A6H F(ab′)2: in vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab′)2. Nucl Med Biol. 1993;20(8):917-927. (Pubitemid 23338075)
24. National Research Council, Commitee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academics Press; 2011.
25. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation. 1996;62(6):876-877. (Pubitemid 26332860)
26. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing [brief communication]. Tissue Antigens. 1998;52(4):397-401. (Pubitemid 28467017)
27. Sandmaier BM, Storb R, Bennett KL, Appelbaum FR, Santos EB. Epitope specificity of CD44 for monoclonal antibody dependent facilitation of marrow engraftment in a canine model. Blood. 1998;91(9):3494-3502. (Pubitemid 28193904)
28. Loughran TP Jr, Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell Immunol. 1985;95(2):207-217. (Pubitemid 16222349)
29. Raff RF, Deeg HJ, Farewell VT, DeRose S, Storb R. The canine major histocompatibility complex: population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens. 1983;21(5):360-373. (Pubitemid 13093899)
30. Storb R, Raff RF, Graham T, et al. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys. 1993;26(2):275-283. (Pubitemid 23156974)
31. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89(8):3048-3054. (Pubitemid 27172593)
32. Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci. 1990;40(1):11-15. (Pubitemid 20061872)
33. Yu C, Ostrander E, Bryant E, Burnett R, Storb R. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation. 1994;58(6):701-706. (Pubitemid 24317770)
34. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240(4855):1024-1026.
35. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, Elmroth K. RBE of alpha-particles from (211)At for complex DNA damage and cell survival in relation to cell cycle position. Int J Radiat Biol. 2011;87(4):372-384.
36. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med. 1980;152(4):842-852. (Pubitemid 10010870)
37. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol. 1983;79(5):546-552. (Pubitemid 13092899)
38. Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood. 1991;78(7):1864-1874.
39. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res. 1992;52(5):1228-1234.
40. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights [review]. Gastroenterology. 2001;120(1):250-260. (Pubitemid 32061889)
41. Prickett TC, McKenzie JL, Hart DN. Characterization of interstitial dendritic cells in human liver. Transplantation. 1988;46(5):754-761. (Pubitemid 19017054)
42. Miyata E, Masuya M, Yoshida S, et al. Hematopoietic origin of hepatic stellate cells in the adult liver. Blood. 2008;111(4):2427-2435. (Pubitemid 351451456)
43. Johansson AG, Lovdal T, Magnusson KE, Berg T, Skogh T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology. 1996;24(1):169-175. (Pubitemid 26249430)
44. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment [review]. Int J Radiat Oncol Biol Phys. 1995;31(5):1237-1248.
45. Harb R, Xie G, Lutzko C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology. 2009;137(2):704-712.
46. Lindencrona U, Nilsson M, Forssell-Aronsson E. Similarities and differences between free 211At and 125I: transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nucl Med Biol. 2001;28(1):41-50. (Pubitemid 32162121)
47. Shellabarger CJ, Durbin PW, Parrott MW, Hamilton JG. Effects of thyroxine and KSCN on capacity of rat thyroid gland to accumulate astatine211. Proc Soc Exp Biol Med. 1954;87(3):626-629.
48. Ron E, Brenner A. Non-malignant thyroid diseases after a wide range of radiation exposures [review]. Radiat Res. 2010;174(6):877-888.
49. Kuhr CS, Allen MD, Junghanss C, et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation. 2002;73(9):1487-1493. (Pubitemid 34547472)